Novavax’s Covid-19 vaccine gets approval in South Korea for adolescents
The approval was based on findings from a paediatric expansion of the Phase III PREVENT-19 clinical trial of Nuvaxovid.

The approval was based on findings from a paediatric expansion of the Phase III PREVENT-19 clinical trial of Nuvaxovid.
The clinical trial of GreenLight’s Covid-19 booster vaccine is anticipated to commence this year.
The takeover will offer Samsung Biologics with biosimilar development expertise and future performance in new drug development.
Under the deal, Kukbo will gain exclusive rights to market opaganib for Covid-19 in the region.
Biogen is eligible to receive up to $50m from Samsung Biologics on meeting some commercial milestones.
SK bioscience will handle the manufacturing and commercialisation of the vaccine in South Korea.
In a study, oral CP-COV03 plus dexamethasone was found to be 2.1 times effective than dexamethasone alone.
The partnership between Enzychem and Cadila is expected to manufacture 80 million or more doses of the vaccine next year.
Thank you for subscribing to Pharmaceutical Technology